|
    ALEC U.S.: Nasdaq

    Alector Inc.

    ALECUS
    After Hours
    Last Updated: Jan 20, 2022 5:29 p.m. EST Delayed quote

    $ 15.73

    0.00 0.00%
    After Hours Volume: 487.63K
    Close Chg Chg %
    $15.73 -0.44 -2.72%
    Advanced Charting
    Volume: 796.59K 65 Day Avg: 617.71K
    129% vs Avg
    15.66 Day Range 16.76
    15.04 52 Week Range 43.32

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ALEC Overview

    Performance

    5 Day
    • -7.85%
    1 Month
    • -33.68%
    3 Month
    • -33.71%
    YTD
    • -23.83%
    1 Year
    • -2.96%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 8 Full Ratings

    Recent News

    Alector: Study Shows AL001 Could Slow Dementia Progression

    Read full story

    Glaxo Responds to Elliott’s Broadside, Announces $700M Deal for 2 Brain Drugs

    Alector started at buy at BofA Securities

    Read full story

    13Ds Filings

    Read full story

    NortonLifeLock and Bancorp See Activist Actions

    Read full story

    Dave & Busters, International Flavors, Trinity Industries, 13D Filings

    Alector started at buy with $44 stock price target at Stifel Nicolaus

    Read full story

    Wall Street is ditching amyloid-based Alzheimer’s drugs — it shouldn't, scientists say

    Alector's stock opens below IPO price, then swings above it

    Alector's stock opens at $18.70, or 1.6% below IPO price of $19 before turning higher

    Biopharma company Alector prices IPO at $19, midpoint of price range

    Alector sets IPO terms to value company at up to $1.4 billion

    Alector Inc (ALEC) President and COO Shehnaaz Suliman Sold $3.4 million of Shares

    on GuruFocus.com

    GlaxoSmithKline Makes Another Big Bet on Brain Drugs

    on GuruFocus.com

    Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Alector (ALEC)

    on TipRanks.com

    Alector Inc (ALEC) CEO Arnon Rosenthal Sold $2.8 million of Shares

    on GuruFocus.com

    Alector Inc (ALEC) CEO Arnon Rosenthal Sold $5 million of Shares

    on GuruFocus.com

    Alector Inc (ALEC) CEO Arnon Rosenthal Sold $5 million of Shares

    on GuruFocus.com

    Alector (ALEC) Lags Q3 Earnings and Revenue Estimates

    on Zacks.com

    Alector (ALEC) Earnings Expected to Grow: Should You Buy?

    on Zacks.com

    Alector Inc (ALEC) CEO Arnon Rosenthal Sold $2.8 million of Shares

    on GuruFocus.com

    Alector Inc (ALEC) CEO Arnon Rosenthal Sold $5.2 million of Shares

    on GuruFocus.com

    A Look at Alector’s Risk Factors After Executive Shakeup

    on TipRanks.com

    Why Alector Shares Are Diving Today

    on Motley Fool

    BTIG Sticks to Its Buy Rating for Alector (ALEC)

    on TipRanks.com

    Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

    on Zacks.com

    Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for

    on Zacks.com

    Alector's (ALEC) Shares March Higher, Can It Continue?

    on Zacks.com

    Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates

    on Zacks.com

    Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates

    on Zacks.com

    Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More

    on Zacks.com

    Alector Surging on GlaxoSmithKline Deal; Analyst Remains Positive

    on TipRanks.com

    Alector Inc.

    Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.